How an Unproven Alzheimer’s Drug Bought Authorised



Although a few of its personal senior officers mentioned there was little proof of profit for sufferers, the F.D.A. nonetheless greenlighted Biogen’s Aduhelm, or aducanumab.



Source link

Spread the love

Leave a Reply

Your email address will not be published. Required fields are marked *